NK Cells With T-Dxd for Hard-to-Treat Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two experimental treatments: special immune cells (NK cells) and a cancer-targeting drug called T-Dxd. It's for patients with breast cancer that hasn't responded to standard treatments and has spread or cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced breast cancer (metastatic or unresectable) that no longer responds to standard treatments
- At least one measurable tumor spot visible on imaging (≥2 cm by chest X-ray or ≥1 cm by CT/MRI)
- Age 18 or older
- For triple-negative breast cancer: must have previously received Sacituzumab govitecan or similar drug
- Good heart, lung, kidney, and liver function, and adequate blood cell counts
- Must stay within 2 hours of the study site for the first 4 weeks after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new kind of immune cell therapy (NK cells) designed to target and attack stomach cancer that has spread to the lining of the abdomen. It combines this with standard surgery and chemotherapy to see if it can help control the cancer.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This early-stage trial tests a new type of immune cell therapy (called CAR/IL-15 NK cells) designed to target and destroy precancerous lesions in the mouth. The therapy may help prevent these lesions from becoming cancer or coming back.
This trial tests a new treatment using immune cells called NK cells combined with chemotherapy (gemcitabine) and possibly naxitamab for people with a certain type of advanced breast cancer that has spread. It aims to see if this approach can help when standard treatments have stopped working.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.